autoimmune disease

2 Biotechs Battling Immune Diseases
2 Biotechs Battling Immune Diseases
Motley Fool
Rigel Pharmaceuticals
Momenta Pharmaceuticals
autoimmune disease
biologics
small molecule drugs
Flag link:
After closing one of China's biggest-ever raises, I-Mab Biopharma nabs $104M Nasdaq IPO
After closing one of China's biggest-ever raises, I-Mab Biopharma nabs $104M Nasdaq IPO
Fierce Biotech
IPOs
China
NASDAQ
I-Mab Biopharma
autoimmune disease
cancer
Flag link:
Upcoming events – Wave takes on Huntington's and Argenx goes subcutaneous
Upcoming events – Wave takes on Huntington's and Argenx goes subcutaneous
EP Vantage
Wave Life Sciences
WVE-120101
Huntington's disease
Argenx
efgartigimod
autoimmune disease
Flag link:
J&J's Remicade losing ground in Quebec health plan despite court victory
J&J's Remicade losing ground in Quebec health plan despite court victory
Yahoo/Reuters
JNJ
Canada
Quebec
Remicade
autoimmune disease
Flag link:
Pandion, Astellas sign $900m deal for pancreas-targeted immunomodulators
Pandion, Astellas sign $900m deal for pancreas-targeted immunomodulators
Pharmaceutical Business Review
Astellas
Pandion Therapeutics
immunomodulators
autoimmune disease
Pancreas
Flag link:
CAR-T cells as 'bait' show promise in autoimmune disease
CAR-T cells as 'bait' show promise in autoimmune disease
Fierce Biotech
CAR-T
autoimmune disease
Flag link:
Oxford spinout MiroBio bags £27M for autoimmune R&D
Oxford spinout MiroBio bags £27M for autoimmune R&D
Fierce Biotech
MiroBio
autoimmune disease
R&D
Flag link:
Cabaletta Bio Files for $100 Million IPO
Cabaletta Bio Files for $100 Million IPO
CP Wire
Cabaletta Bio
IPOs
autoimmune disease
DSG3-CAART
pemphigus vulgaris
Flag link:
Promising autoimmune biotech gets $40 million as celiac drug is pushed to clinic
Promising autoimmune biotech gets $40 million as celiac drug is pushed to clinic
Endpoints
celiac disease
autoimmune disease
Anokion
Kanyos Bio
Kan-101
Flag link:
FDA approves Rituxan biosimilar
FDA approves Rituxan biosimilar
Beckers Hospital Review
Pfizer
biosimilars
FDA
Ruxience
cancer
autoimmune disease
Genentech
Flag link:
Alexion's cash cow Soliris just got fatter as FDA greenlights another blockbuster indication
Alexion's cash cow Soliris just got fatter as FDA greenlights another blockbuster indication
Endpoints
Alexion
Soliris
FDA
autoimmune disease
NMOSD
Flag link:
AstraZeneca spinout Viela Bio pockets $75M on its way to BLA for autoimmune drug
AstraZeneca spinout Viela Bio pockets $75M on its way to BLA for autoimmune drug
Endpoints
Viela Bio
AstraZeneca
autoimmune disease
Flag link:
Genentech lines up a new autoimmune R&D alliance on a 'potentially transformative' tech
Genentech lines up a new autoimmune R&D alliance on a 'potentially transformative' tech
Endpoints
Parvus Therapeutics
Genentech
drug discovery
autoimmune disease
Flag link:
Salix grabs ex-Asia rights to Mitsubishi Tanabe autoimmune drug
Salix grabs ex-Asia rights to Mitsubishi Tanabe autoimmune drug
Fierce Biotech
Salix
Mitsubishi Tanabe Pharma
amiselimod
Bausch Health
autoimmune disease
ulcerative colitis
Flag link:
Celgene taps Exscientia’s AI drug discovery tech for 3 new programs
Celgene taps Exscientia’s AI drug discovery tech for 3 new programs
Fierce Biotech
Celgene
Exscientia
artificial intelligence
oncology
autoimmune disease
drug discovery
Flag link:
Principia, AbbVie walk away from 2017 partnership for inflammatory, autoimmune drugs
Principia, AbbVie walk away from 2017 partnership for inflammatory, autoimmune drugs
Endpoints
AbbVie
Principia Biopharma
inflammatory diseases
autoimmune disease
Flag link:
Lilly, Aduro Biotech in Immunotherapy Alliance
Lilly, Aduro Biotech in Immunotherapy Alliance
Contract Pharma
Eli Lilly
Aduro BioTech
autoimmune disease
drug development
Flag link:
Johnson & Johnson drops OSE’s rheumatoid arthritis drug
Johnson & Johnson drops OSE’s rheumatoid arthritis drug
Fierce Biotech
JNJ
OSE Immuotherapeutics
FR104
autoimmune disease
rheumatoid arthritis
Flag link:
AbbVie, Sanofi-backed Principia offers an $86M IPO after burning through $148M for pipeline work
AbbVie, Sanofi-backed Principia offers an $86M IPO after burning through $148M for pipeline work
Endpoints
IPOs
Principia Biopharma
Sanofi
AbbVie
PRN1008
autoimmune disease
Flag link:
Bristol-Myers Squibb signs new development agreement for autoimmune disorders treatments
Bristol-Myers Squibb signs new development agreement for autoimmune disorders treatments
GoinPharma
autoimmune disease
Bristol-Myers Squibb
Flag link:

Pages